Częstość występowania incydentaloma tarczycy w Isfahanie, Iran - badanie populacyjne

Introduction: Thyroid nodules not detected in palpation but diagnosed following a radiological procedure or during surgery are called thyroid incidentalomas. We designed this study to investigate the prevalence of sonographic thyroid incidentaloma in Isfahan, Iran, for the first time. Material and methods: By a multistage cluster sampling method, 2523 adults were selected randomly. From this group, 2045 had normal thyroid examination. 234 out of the 2045 were selected randomly for thyroid sonography. Thyroid stimulating hormone (TSH), urinary iodine concentrations (UIC) and antithyroid antibodies were measured. Results: The prevalence of thyroid incidentaloma was 13.2% [Confidence interval (CI) 95% = 8–18]. The average age of subjects with and without incidentaloma was 46.1 (12.4) and 38.4 (12.1), respectively (P = 0.002). It was more prevalent in females than in males (19% vs. 10%) [Odds ratio (OR) = 2.59, CI 95% = 1.17–5.76, P value (P) = 0.01]. Median UIC in the incidentaloma group (14 μg/dl) was significantly lower than in the group of subjects without nodules (20 μg/dl) (OR = 0.9, CI 95% = 0.91–0.99, P = 0.02). There was no difference in the levels of TSH and antithyroid antibodies between the two groups (P > 0.05). Mean diameter of nodules was 8.14 (3.43) mm. Conclusions: The prevalence of thyroid incidentaloma was 13.2% in Isfahan. It was higher in females than males and increased with age.Wstęp: Incidentalona to guzki tarczycy niewykrywalne palpacyjnie, lecz zdiagnozowane przypadkowo podczas badania obrazowego lub zabiegu chirurgicznego. Celem badania było określenie po raz pierwszy częstości incidentaloma wykrywanych w badaniu sonograficznym w populacji irackiego miasta Isfahan. Materiał i metody: Metodą wielostopniowego losowania zespołowego wybrano grupę 2523 dorosłych osób. Spośród 2045 osób, u których nie stwierdzono zmian w badaniu palpacyjnym, wytypowano losowo 234 osoby do badania sonograficznego tarczycy. Oznaczono u nich również stężenie hormonu tyreotropowego (TSH, thyroid stimulating hormone), stężenie jodu w moczu (UIC, urinary iodine concentration) oraz przeciwciała przeciwtarczycowe. Wyniki: Incidentaloma tarczycy wykryto u 13,2% badanych (95% przedział ufności [CI] = 8–11). Średni wiek osób, u których wykazano obecność guzków wynosił 46,1 (± 12,4) lat, natomiast osób bez guzków - 38,4 (± 12,1) lat (p = 0,002). Incidentaloma występowały częściej u kobiet niż u mężczyzn (19 vs. 10%; iloraz szans [OR] = 2,59; 95% CI = 1,17–5,76; p = 0,01). Obie grupy nie różniły się pod względem stężeń TSH i przeciwciał przeciwtarczycowych (p > 0,05). Średnica guzków wynosiła średnio 8,14 (± 3,43) mm. Wnioski: Częstość incidentaloma tarczycy w populacji Isfahanu wynosiła 13,2%; była większa u kobiet niż u mężczyzn i wzrastała z wiekiem

Sonographic and functional characteristics of thyroid nodules in a population of adult people in Isfahan

Wstęp: Celem badania była ocena cech sonograficznych zmian ogniskowych tarczycy u mieszkańców Isfahanu, obszaru w cenralnym Iranie, który wcześniej charakteryzował się niedoborem jodu. Materiał i metody: W przekrojowym badaniu przeprowadzonym w 2006 roku wybrano próbę liczącą 2523 dorosłych osób (wiek > 20 lat) metodą wielostopniowego losowania grupowego. Spośród tej grupy, 263 ochotników poddano badaniom sonograficznym. Badanie tarczycy przeprowadzili doświadczeni specjaliści w zakresie ultrasonografii. Ponadto oznaczono stężenia T3, T4, T3RU, TSH, TPO Ab i Tg Ab w surowicy oraz wydalanie jodu z moczem. Wyniki: Kobiety stanowiły 46% grupy poddanej badaniom sonograficznym (n = 263). Średnia wieku wynosiła 35,5 lat (zakres 20-64 lat). Mediana stężenia jodu w moczu wynosiła 19.4 μg/dl. Obecność zmian ogniskowych tarczycy wykazano w badaniu sonograficznym u 22,4% osób z badanej grupy; u 30% kobiet i 16,3% mężczyzn (OR = 2,2; p = 0,01). Częstość występowania zmian ogniskowych tarczycy zwiększała się z wiekiem (p = 0,006). Zmiany ogniskowe tarczycy występowały częściej u osób z niedoczynnością tarczycy niż w grupie z eutyreozą (35,1% v. 20,5%, OR = 2,1; p = 0,04). Nie stwierdzono korelacji między stężeniem jodu w moczu ani stężeniem autoprzeciwciał a występowaniem zmian ogniskowych tarczycy w badaniu sonograficznym. Wnioski: Częstość występowania zmian ogniskowych tarczycy oceniana na podstawie wyników badania sonograficznego jest nadal duża w badanej populacji, mimo prawidłowego stężenia jodu w moczu. (Endokrynol Pol 2010; 61 (2): 188-191)Introduction: The aim of this study was to investigate the current status of sonographic characteristics of thyroid nodules in Isfahan, a previously iodine deficient area in central Iran. Material and methods: In a cross-sectional study conducted in 2006, 2523 adult people (age > 20 years) were selected by a multistage clustering sampling method. Of these people, 263 volunteered persons were underwent sonographic evaluation. Thyroid examination was done by two expert sonographers. Serum T3, T3, T3RU, TSH, TPO Ab and Tg Ab, and urinary iodine were measured. Results: Forty-six per cent of the 263 people were women. Their mean age was 35.5 years with a range of 20-64 years. Median urinary iodine was 19.4 μg/dL. The prevalence of thyroid nodules on sonography was 22.4% in the whole group; 30% in women and 16.3% in men (OR = 2.2, P = 0.01). The prevalence of thyroid nodules increased with age (P = 0.006). The prevalence of thyroid nodules was higher in hypothyroid people than in euthyroid people (35.1% v. 20.5%, OR = 2.1, P = 0.04). Neither urinary iodine nor autoantibody concentrations correlated with the prevalence of thyroid nodules in sonography. Conclusions: The prevalence of thyroid nodule by sonography is still high despite relatively normal urinary iodine in this population. (Pol J Endocrinol 2010; 61 (2): 188-191

Hypocalcemic seizure and related factors after neonatal period; A single-center, retrospective study

      Seizures are the most common disorder of the central nervous system in childhood and constitute a significant number of admissions to the pediatric emergency departments. The aim of this study is evaluate the etiology of hypocalcemic seizures in pediatrics. A single-center, hospital based descriptive study was done in the academic referral center for hypocalcemic seizure of Tehran University of Medical Sciences, Iran. Data was evaluated based on the medical records of each patient. Case files of these children’s were analyzed for age at presentation, sex, weight, clinical features, biochemical parameters (serum calcium, magnesium, phosphorus and alkaline phosphatase) ,type of seizure, history of previous seizure and history of drug intake.  A total 38 children with hypocalcemic seizure, consisting of 19 boys and 19 girls, with ages ranging from one month to 14 years, were enrolled in this study. The most common patterns of seizures were generalized seizures (83.8%). the mean levels of serum alkaline phosphatase was significantly greater in patients under the age of 2 years (1234 ± 541.03) rather above than 7 years of age (922.75 ± 147.45) (p = .021). Rickets was the commonest cause of seizures rickets were diagnosis in  80.8% subjects  under 2 years of age, whereas none of those over 7 years old had not rickets , these  results were statistically significant (p = .015). Current observational study indicates that rickets could be a major cause of hypocalcemic convulsion in infants and children. Screening children presenting with hypocalcemic convulsions for rickets and/or other cause of hypocalcemia can help in early diagnosis and institution of specific therapy.

Prevalence of Nocturnal Enuresis in School-age Children in Rafsanjan

Introduction: Nocturnal enuresis is an important developmental problem for school age children and it can cause emotional and social problems for children and their families. This study was aimed to determine the prevalence of enuresis in school children aged 6-8 years in Rafsanjan, Iran, during 2014.Material and Methods: In this cross-sectional study, 1080 school children aged 6-8 were selected using a random cluster sampling method. Questionnaires were distributed among the children to be answered by their parents.Results: The overall prevalence of nocturnal enuresis was10.6% (CI 95%: 8.76 – 12.44); 91.3 % of them had primary and 8.7% had secondary nocturnal enuresis. Prevalence in girls and boys were 8.44% and 12.3% respectively. Factors such as parental education, family income, and age were significantly associated with nocturnal enuresis.Conclusions: The results showed that the prevalence of nocturnal enuresis in our study is average. Since a minority of families seek medical advice and treatment for their children, family education and awareness is essential in this regard.Keywords: Nocturnal enuresis, Child, Prevalence, School

Hydatidosis of the Pelvic Cavity: A Big Masquerade

We report and discuss a case of primary hydatidosis of the pelvic cavity in a woman who presented with severe weight loss and abdominal pain. This unusual presentation was initially considered as a tumor process until surgical exploration and microscopic studies confirmed the diagnosis. The gynecologists should be aware of possibility of primary hydatid cyst of the pelvic cavity and should be considered in the differential diagnosis of cystic pelvic masses, especially in areas where the disease is endemic

Global burden of chronic respiratory diseases and risk factors, 1990–2019: an update from the Global Burden of Disease Study 2019

Background: Updated data on chronic respiratory diseases (CRDs) are vital in their prevention, control, and treatment in the path to achieving the third UN Sustainable Development Goals (SDGs), a one-third reduction in premature mortality from non-communicable diseases by 2030. We provided global, regional, and national estimates of the burden of CRDs and their attributable risks from 1990 to 2019. Methods: Using data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, we estimated mortality, years lived with disability, years of life lost, disability-adjusted life years (DALYs), prevalence, and incidence of CRDs, i.e. chronic obstructive pulmonary disease (COPD), asthma, pneumoconiosis, interstitial lung disease and pulmonary sarcoidosis, and other CRDs, from 1990 to 2019 by sex, age, region, and Socio-demographic Index (SDI) in 204 countries and territories. Deaths and DALYs from CRDs attributable to each risk factor were estimated according to relative risks, risk exposure, and the theoretical minimum risk exposure level input. Findings: In 2019, CRDs were the third leading cause of death responsible for 4.0 million deaths (95% uncertainty interval 3.6–4.3) with a prevalence of 454.6 million cases (417.4–499.1) globally. While the total deaths and prevalence of CRDs have increased by 28.5% and 39.8%, the age-standardised rates have dropped by 41.7% and 16.9% from 1990 to 2019, respectively. COPD, with 212.3 million (200.4–225.1) prevalent cases, was the primary cause of deaths from CRDs, accounting for 3.3 million (2.9–3.6) deaths. With 262.4 million (224.1–309.5) prevalent cases, asthma had the highest prevalence among CRDs. The age-standardised rates of all burden measures of COPD, asthma, and pneumoconiosis have reduced globally from 1990 to 2019. Nevertheless, the age-standardised rates of incidence and prevalence of interstitial lung disease and pulmonary sarcoidosis have increased throughout this period. Low- and low-middle SDI countries had the highest age-standardised death and DALYs rates while the high SDI quintile had the highest prevalence rate of CRDs. The highest deaths and DALYs from CRDs were attributed to smoking globally, followed by air pollution and occupational risks. Non-optimal temperature and high body-mass index were additional risk factors for COPD and asthma, respectively. Interpretation: Albeit the age-standardised prevalence, death, and DALYs rates of CRDs have decreased, they still cause a substantial burden and deaths worldwide. The high death and DALYs rates in low and low-middle SDI countries highlights the urgent need for improved preventive, diagnostic, and therapeutic measures. Global strategies for tobacco control, enhancing air quality, reducing occupational hazards, and fostering clean cooking fuels are crucial steps in reducing the burden of CRDs, especially in low- and lower-middle income countries

The global burden of adolescent and young adult cancer in 2019 : a systematic analysis for the Global Burden of Disease Study 2019

Background In estimating the global burden of cancer, adolescents and young adults with cancer are often overlooked, despite being a distinct subgroup with unique epidemiology, clinical care needs, and societal impact. Comprehensive estimates of the global cancer burden in adolescents and young adults (aged 15-39 years) are lacking. To address this gap, we analysed results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, with a focus on the outcome of disability-adjusted life-years (DALYs), to inform global cancer control measures in adolescents and young adults. Methods Using the GBD 2019 methodology, international mortality data were collected from vital registration systems, verbal autopsies, and population-based cancer registry inputs modelled with mortality-to-incidence ratios (MIRs). Incidence was computed with mortality estimates and corresponding MIRs. Prevalence estimates were calculated using modelled survival and multiplied by disability weights to obtain years lived with disability (YLDs). Years of life lost (YLLs) were calculated as age-specific cancer deaths multiplied by the standard life expectancy at the age of death. The main outcome was DALYs (the sum of YLLs and YLDs). Estimates were presented globally and by Socio-demographic Index (SDI) quintiles (countries ranked and divided into five equal SDI groups), and all estimates were presented with corresponding 95% uncertainty intervals (UIs). For this analysis, we used the age range of 15-39 years to define adolescents and young adults. Findings There were 1.19 million (95% UI 1.11-1.28) incident cancer cases and 396 000 (370 000-425 000) deaths due to cancer among people aged 15-39 years worldwide in 2019. The highest age-standardised incidence rates occurred in high SDI (59.6 [54.5-65.7] per 100 000 person-years) and high-middle SDI countries (53.2 [48.8-57.9] per 100 000 person-years), while the highest age-standardised mortality rates were in low-middle SDI (14.2 [12.9-15.6] per 100 000 person-years) and middle SDI (13.6 [12.6-14.8] per 100 000 person-years) countries. In 2019, adolescent and young adult cancers contributed 23.5 million (21.9-25.2) DALYs to the global burden of disease, of which 2.7% (1.9-3.6) came from YLDs and 97.3% (96.4-98.1) from YLLs. Cancer was the fourth leading cause of death and tenth leading cause of DALYs in adolescents and young adults globally. Interpretation Adolescent and young adult cancers contributed substantially to the overall adolescent and young adult disease burden globally in 2019. These results provide new insights into the distribution and magnitude of the adolescent and young adult cancer burden around the world. With notable differences observed across SDI settings, these estimates can inform global and country-level cancer control efforts. Copyright (C) 2021 The Author(s). Published by Elsevier Ltd.Peer reviewe

The global burden of cancer attributable to risk factors, 2010-19 : a systematic analysis for the Global Burden of Disease Study 2019

Background Understanding the magnitude of cancer burden attributable to potentially modifiable risk factors is crucial for development of effective prevention and mitigation strategies. We analysed results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 to inform cancer control planning efforts globally. Methods The GBD 2019 comparative risk assessment framework was used to estimate cancer burden attributable to behavioural, environmental and occupational, and metabolic risk factors. A total of 82 risk-outcome pairs were included on the basis of the World Cancer Research Fund criteria. Estimated cancer deaths and disability-adjusted life-years (DALYs) in 2019 and change in these measures between 2010 and 2019 are presented. Findings Globally, in 2019, the risk factors included in this analysis accounted for 4.45 million (95% uncertainty interval 4.01-4.94) deaths and 105 million (95.0-116) DALYs for both sexes combined, representing 44.4% (41.3-48.4) of all cancer deaths and 42.0% (39.1-45.6) of all DALYs. There were 2.88 million (2.60-3.18) risk-attributable cancer deaths in males (50.6% [47.8-54.1] of all male cancer deaths) and 1.58 million (1.36-1.84) risk-attributable cancer deaths in females (36.3% [32.5-41.3] of all female cancer deaths). The leading risk factors at the most detailed level globally for risk-attributable cancer deaths and DALYs in 2019 for both sexes combined were smoking, followed by alcohol use and high BMI. Risk-attributable cancer burden varied by world region and Socio-demographic Index (SDI), with smoking, unsafe sex, and alcohol use being the three leading risk factors for risk-attributable cancer DALYs in low SDI locations in 2019, whereas DALYs in high SDI locations mirrored the top three global risk factor rankings. From 2010 to 2019, global risk-attributable cancer deaths increased by 20.4% (12.6-28.4) and DALYs by 16.8% (8.8-25.0), with the greatest percentage increase in metabolic risks (34.7% [27.9-42.8] and 33.3% [25.8-42.0]). Interpretation The leading risk factors contributing to global cancer burden in 2019 were behavioural, whereas metabolic risk factors saw the largest increases between 2010 and 2019. Reducing exposure to these modifiable risk factors would decrease cancer mortality and DALY rates worldwide, and policies should be tailored appropriately to local cancer risk factor burden. Copyright (C) 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.Peer reviewe

Global investments in pandemic preparedness and COVID-19: development assistance and domestic spending on health between 1990 and 2026

Background The COVID-19 pandemic highlighted gaps in health surveillance systems, disease prevention, and treatment globally. Among the many factors that might have led to these gaps is the issue of the financing of national health systems, especially in low-income and middle-income countries (LMICs), as well as a robust global system for pandemic preparedness. We aimed to provide a comparative assessment of global health spending at the onset of the pandemic; characterise the amount of development assistance for pandemic preparedness and response disbursed in the first 2 years of the COVID-19 pandemic; and examine expectations for future health spending and put into context the expected need for investment in pandemic preparedness. Methods In this analysis of global health spending between 1990 and 2021, and prediction from 2021 to 2026, we estimated four sources of health spending: development assistance for health (DAH), government spending, out-of-pocket spending, and prepaid private spending across 204 countries and territories. We used the Organisation for Economic Co-operation and Development (OECD)'s Creditor Reporting System (CRS) and the WHO Global Health Expenditure Database (GHED) to estimate spending. We estimated development assistance for general health, COVID-19 response, and pandemic preparedness and response using a keyword search. Health spending estimates were combined with estimates of resources needed for pandemic prevention and preparedness to analyse future health spending patterns, relative to need. Findings In 2019, at the onset of the COVID-19 pandemic, US$9·2 trillion (95$7·3 trillion (95% UI 7·2–7·4) in 2019; 293·7 times the $24·8 billion (95$43·1 billion in development assistance was provided to maintain or improve health. The pandemic led to an unprecedented increase in development assistance targeted towards health; in 2020 and 2021, $1·8 billion in DAH contributions was provided towards pandemic preparedness in LMICs, and$37·8 billion was provided for the health-related COVID-19 response. Although the support for pandemic preparedness is 12·2% of the recommended target by the High-Level Independent Panel (HLIP), the support provided for the health-related COVID-19 response is 252·2% of the recommended target. Additionally, projected spending estimates suggest that between 2022 and 2026, governments in 17 (95% UI 11–21) of the 137 LMICs will observe an increase in national government health spending equivalent to an addition of 1% of GDP, as recommended by the HLIP. Interpretation There was an unprecedented scale-up in DAH in 2020 and 2021. We have a unique opportunity at this time to sustain funding for crucial global health functions, including pandemic preparedness. However, historical patterns of underfunding of pandemic preparedness suggest that deliberate effort must be made to ensure funding is maintained